COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2024
08/04/2024
Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 mars 2024
08/04/2024
Nombre total de droits de vote et d’actions composant le capital social au 31 mars 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Charenton- [...]
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents
08/04/2024
COMBINED GENERAL MEETING OF APRIL 30, 2024 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at 2:30 p.m. (CET) at [...]
Sanofi - AGM 30.04.2024 - Mise à disposition des documents préparatoires
08/04/2024
ASSEMBLEE GENERALE MIXTE DU 30 AVRIL 2024 MODALITES DE MISE A DISPOSITION OU DE CONSULTATION DES DOCUMENTS PREPARATOIRES Les actionnaires de la Société sont invités à participer à l’assemblée générale mixte qui se [...]
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
08/04/2024
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08/04/2024
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors
08/04/2024
CAMBRIDGE, United Kingdom, April 08, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, is today presenting data on its M300 program [...]
EssilorLuxottica: First-Quarter 2024 Revenue Conference Call Invitation
08/04/2024
First-Quarter 2024 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our First-Quarter 2024 Revenue [...]
EssilorLuxottica: First-Quarter 2024 Revenue Conference Call Invitation
08/04/2024
First-Quarter 2024 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our First-Quarter 2024 Revenue [...]
Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer
08/04/2024
Otis will lead team developing brain implants for medical use NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as [...]
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
08/04/2024
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of [...]
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
08/04/2024
Data from this large safety-trial also published in The Journal of the American College of Cardiology MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a [...]
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer
08/04/2024
Chi Li, PhD, MBA, RAC adds over 20 years of global regulatory experience and success to the Curevo Vaccine executive team SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical- [...]
Novo Nordisk A/S - share repurchase programme
08/04/2024
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 08 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the [...]
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
08/04/2024
BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Invitation to the annual shareholders’ meeting
08/04/2024
The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and the Board of Directors [...]
Regional Health Properties Reports Fourth Quarter and Full Year 2023 Financial Results
08/04/2024
Collected 93% of Contractual Rent [ 1] Strong Operator Rent Coverage ATLANTA, GA, April 08, 2024 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “Regional Health,” “we”, “us” or “our”) (NYSE [...]
TRACON Pharmaceuticals Announces Reverse Stock Split
08/04/2024
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform to advance its [...]
Quanta Presents Preclinical Data for QTX3544, a Potent and Selective G12V-preferring Multi-KRAS Inhibitor, in Late-Breaking Session at Annual AACR Meeting 2024
08/04/2024
–Strong anti-tumor activity, favorable oral bioavailability and drug-like properties demonstrated in preclinical models – –Data support ongoing IND-enabling studies for planned clinical evaluation in KRAS G12V -driven [...]

Pages